Contact
Please use this form to send email to PR contact of this press release:
$10 Million in New Equity Funding Coupled with Recent Short Squeeze Activity; Cancer Immunotherapy Company NASDAQ: RENB
TO:
The Hon. Mark Dybul, MD, CEO
Renovaro Biosciences Inc
+1 732-780-5036